1997
Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras
Sultan P, Schechner J, McNiff J, Hochman P, Hughes C, Lorber M, Askenase P, Pober J. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nature Biotechnology 1997, 15: 759-762. PMID: 9255790, DOI: 10.1038/nbt0897-759.Peer-Reviewed Original ResearchConceptsSkin graftsLFA-3Human T-cell infiltrationIsotype-matched control antibodyT cell infiltrationSkin graft rejectionHuman skin graftsHuman skin allograftsCD2-LFA-3 interactionHuman LFA-3Microvascular injuryGraft rejectionLeukocyte infiltrationSkin allograftsImmune modulatorsControl antibodyInjury modelImmunodeficient miceImmune reactionsMouse/human chimeraMurine mAbsCD2 interactionPrincipal ligandGraftInjury
1988
LYTIC ANTI-ENDOTHELIAL CELL ANTIBODIES IN HAEMOLYTIC-URAEMIC SYNDROME
Leung D, Havens P, Moake J, Kim M, Pober J. LYTIC ANTI-ENDOTHELIAL CELL ANTIBODIES IN HAEMOLYTIC-URAEMIC SYNDROME. The Lancet 1988, 332: 183-186. PMID: 2899661, DOI: 10.1016/s0140-6736(88)92287-8.Peer-Reviewed Original ResearchConceptsAnti-endothelial cell antibodiesHaemolytic uraemic syndromeThrombotic thrombocytopenic purpuraCell antibodiesComplement-fixing IgGDisorder of immunoregulationAnti-endothelial antibodiesEndothelial cell antigensCultured human umbilical vein endothelial cellsGamma-interferon treatmentHuman umbilical vein endothelial cellsUmbilical vein endothelial cellsAdult patientsVein endothelial cellsThrombocytopenic purpuraIgM antibodiesVascular injuryInterferon treatmentUraemic syndromeGamma interferonCell antigensControl seraEndothelial cellsAntibodiesSerum